3D Total Body Digital SPECT: Clinical Practice and Advanced Quantitative Applications

Non-CME

Complimentary Breakfast

7:10-7:50am
Friday November 3, 2023

Frank Anstett
Director Clinical Marketing
Spectrum Dynamics Medical
Blue Earth

will be conducting a Non–CME Meal Activity

“POSLUMA (flotufolastat F18) injection: PET Imaging Agent Overview”

* Presented By: Dr. Louis Mazzarelli, Yale New Haven Health, Lawrence and Memorial abd Westerly Hospitals

Event is open to all registrants on

Friday, November 3rd, 2023, 12 PM

In the

Marriott Hartford Downtown

Capital Room
Illucix® for ⁶⁸Ga PSMA-11 PET
Imaging of Prostate Cancer
Non-CME Presentation

Robert Bridwell, MD, MBA

Dr. Bridwell is a subject matter expert in advanced diagnostic imaging, with a specialization in oncology. He has performed over 3000 CME hours of education over the last five years. Dr. Bridwell is board certified in both Internal Medicine and Nuclear Medicine and completed his Nuclear Medicine Fellowship at Walter Reed Army Medical Center in Washington, D.C. At Walter Reed, he implemented and served as medical director of the PET/CT program. He has held academic appointments at the Uniformed Services University of Health Sciences, and also at the University of Texas, San Antonio. Dr. Bridwell serves as Medical Advisor for SOFIE and provides peer to peer services to a network of over 300 scanners in the United States. He has recently run the nationwide peer to peer support program and physician training for GE Healthcare during the launch of FES PET/CT. With respect to PSMA PET/CT he has personally reviewed over 6000 scans.

Event is open to all registered attendees
Continental breakfast and coffee will be served

Date: Saturday, November 4th
Time: 7:00 AM
Location: Marriott Hartford Downtown Capital Room

INDICATIONS AND USAGE

ILLUCIX, after radiolabeling with Ga 68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
• With suspected metastasis who are candidates for initial definitive therapy
• With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
• For selection of patients with metastatic prostate cancer, for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk for Misinterpretation
Image interpretation errors can occur with ILLUCCIX PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget’s disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

Imaging Prior to Initial Definitive or Suspected Recurrence Therapy
The performance of ILLUCCIX for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of ILLUCCIX for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score.

Imaging to Select Patients for Lutetium Lu 177 Vipivotide Tetraxetan Therapy
The interpretation of ILLUCCIX PET may differ depending on imaging readers. ILLUCCIX PET interpretations to select patients for lutetium Lu 177 vipivotide tetraxetan therapy may be more consistent when judging gallium Ga 68 gozetotide uptake in any one tumor lesion compared to judging uptake for all lesions larger than size criteria. Multidisciplinary consultation to select patients for lutetium Lu 177 vipivotide tetraxetan therapy is recommended, particularly for ILLUCCIX imaging that a single reader finds borderline or difficult to interpret, or when patient eligibility hinges only on judgment of gallium Ga 68 gozetotide uptake for all lesions larger than size criteria.

Radiation Risks
Gallium Ga 68 gozetotide contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS

The safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.8 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.

In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at ≥0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%). Adverse reactions occurring at a rate of <0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills.

DRUG INTERACTIONS

Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established.

Please note that this information is not comprehensive.
Please see the Full Prescribing Information at illuccix.com/prescribinginformation

You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-9638 or emailing pharmaovigilance@telixpharma.com.

Illucix® is a trademark of Telix Pharmaceuticals (US) Inc. © 2023 Telix Pharmaceuticals (US) Inc. All rights reserved. US-ILL-2200097 v2 1/2023
Join us for the upcoming event:

**CLINICAL ADVANTAGE OF CARDIAC PET WITH MYOCARDIAL BLOOD FLOW PERFORMED WITH N13 AMMONIA**

Non-CME Presentation

Presented by: **April Mann, MBA, CNMT, NCT, RT(N)**

Date: **Saturday, November 4, 2023 at 12:15pm**

Location: **Marriott Harford Downtown – Capital Room**

Contact us: clinical@ionetix.com

For more information, visit IONETIX.com